These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 37425051)

  • 1. Intelligent nanotherapeutic strategies for the delivery of CRISPR system.
    Chen C; Zhong W; Du S; Li Y; Zeng Y; Liu K; Yang J; Guan X; Han X
    Acta Pharm Sin B; 2023 Jun; 13(6):2510-2543. PubMed ID: 37425051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas-mediated genome editing in mice for the development of drug delivery mechanism.
    Sowbhagya R; Muktha H; Ramakrishnaiah TN; Surendra AS; Tanvi Y; Nivitha K; Rajashekara S
    Mol Biol Rep; 2023 Sep; 50(9):7729-7743. PubMed ID: 37438488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The feasibility of oral targeted drug delivery: Gut immune to particulates?
    Ren Y; Wu W; Zhang X
    Acta Pharm Sin B; 2023 Jun; 13(6):2544-2558. PubMed ID: 37425061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wearable patches for transdermal drug delivery.
    He J; Zhang Y; Yu X; Xu C
    Acta Pharm Sin B; 2023 Jun; 13(6):2298-2309. PubMed ID: 37425057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and Prospects in the Treatment of Pancreatic Cancer.
    Duan H; Li L; He S
    Int J Nanomedicine; 2023; 18():3973-3988. PubMed ID: 37489138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized minimal genome-wide human sgRNA library.
    Zhou Y; Wang L; Lu Z; Yu Z; Ma L
    Sci Rep; 2023 Jul; 13(1):11569. PubMed ID: 37464007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas Systems: Programmable Nuclease Revolutionizing the Molecular Diagnosis.
    Pandya K; Jagani D; Singh N
    Mol Biotechnol; 2024 Aug; 66(8):1739-1753. PubMed ID: 37466850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature.
    Yang Y; Cheng N; Luo Q; Shao N; Ma X; Chen J; Luo L; Xiao Z
    Int J Nanomedicine; 2023; 18():3663-3694. PubMed ID: 37427368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomimetic Cell-Derived Nanoparticles: Emerging Platforms for Cancer Immunotherapy.
    Hu T; Huang Y; Liu J; Shen C; Wu F; He Z
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bio-Inspired Nanocarriers Derived from Stem Cells and Their Extracellular Vesicles for Targeted Drug Delivery.
    Abudurexiti M; Zhao Y; Wang X; Han L; Liu T; Wang C; Yuan Z
    Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipose Tissue-Derived Mesenchymal Stem Cell-Derived Exosomes Promote Wound Healing and Tissue Regeneration.
    Lee JH; Won YJ; Kim H; Choi M; Lee E; Ryoou B; Lee SG; Cho BS
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cells, as glioma exosomal immunosuppressive signal multipliers, enhance MDSCs immunosuppressive activity through the miR-21/SP1/DNMT1 positive feedback loop.
    Qiu W; Guo Q; Guo X; Wang C; Li B; Qi Y; Wang S; Zhao R; Han X; Du H; Zhao S; Pan Z; Fan Y; Wang Q; Gao Z; Li G; Xue H
    J Nanobiotechnology; 2023 Jul; 21(1):233. PubMed ID: 37481646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma.
    Li T; Jiao J; Ke H; Ouyang W; Wang L; Pan J; Li X
    Front Immunol; 2023; 14():1200201. PubMed ID: 37457718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal Stem Cells and Exosomes: A Novel Therapeutic Approach for Corneal Diseases.
    Bhujel B; Oh SH; Kim CM; Yoon YJ; Kim YJ; Chung HS; Ye EA; Lee H; Kim JY
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal PPARĪ³ derived from macrophages suppresses LPS-induced peritonitis by negative regulation of CD14/TLR4 axis.
    Meng M; Lu M; Feng J; Zhou X; Meng P; Chen L; Zou X; Liu X; Liu L; Gao X; Zhang Y
    Inflamm Res; 2023 Aug; 72(8):1567-1581. PubMed ID: 37438583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-viral approaches for gene therapy and therapeutic genome editing across the blood-brain barrier.
    Xie R; Wang Y; Burger JC; Li D; Zhu M; Gong S
    Med X; 2023; 1(1):6. PubMed ID: 37485250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles.
    Lee DY; Amirthalingam S; Lee C; Rajendran AK; Ahn YH; Hwang NS
    Nanoscale Adv; 2023 Jul; 5(15):3834-3856. PubMed ID: 37496613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxic Tumor-Derived Exosomal miR-199a-3p Promote Gastric Cancer Metastasis via MAP3K4.
    Li L; Wang L; Yang JL; Wang HJ; Wang YY
    J Cancer; 2023; 14(11):2161-2172. PubMed ID: 37497404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment.
    Zou Y; Sun Y; Wang Y; Zhang D; Yang H; Wang X; Zheng M; Shi B
    Nat Commun; 2023 Jul; 14(1):4557. PubMed ID: 37507371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy.
    Li M; Sun J; Shi G
    Front Cell Dev Biol; 2023; 11():1220376. PubMed ID: 37427373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.